Cargando…
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas(1,2). Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydr...
Autores principales: | Flavahan, William A., Drier, Yotam, Liau, Brian B., Gillespie, Shawn M., Venteicher, Andrew S., Stemmer-Rachamimov, Anat O., Suvà, Mario L., Bernstein, Bradley E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831574/ https://www.ncbi.nlm.nih.gov/pubmed/26700815 http://dx.doi.org/10.1038/nature16490 |
Ejemplares similares
-
IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice
por: Richardson, Leland G., et al.
Publicado: (2020) -
Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023) -
Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023) -
Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
por: Radoul, Marina, et al.
Publicado: (2021) -
Epigenome editing strategies for the functional annotation of CTCF insulators
por: Tarjan, Daniel R., et al.
Publicado: (2019)